PFE · Pfizer Inc.
$28.332026-05-17Sector: Healthcare; Industry: Drug Manufacturers - General; Sub-Industry: Pharmaceuticals
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Base · active
$30
+4.2% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($29 · $68) Analysts Range ($24 · $35) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2021.Q4 | $81.3B | — | 30.0% | 7.6% | $22.5B | $12.2B | $34.7B | 4.0% | — | 18.4% | $122.7B | $3.90 | — |
| 2022.Q4 | $100.3B | 23.4% | 43.9% | 9.6% | $39.8B | −$28.2B | $11.6B | 5.8% | — | 30.3% | $140.5B | $5.52 | — |
| 2023.Q4 | $59.6B | -40.6% | 10.4% | 0.0% | $12.7B | −$45.6B | −$32.8B | 8.4% | — | 8.0% | $177.4B | $0.38 | — |
| 2024.Q4 | $63.6B | 6.8% | 30.4% | 0.0% | $19.4B | $5.7B | $25.1B | 6.6% | — | 11.4% | $162.1B | $1.41 | — |
| 2025.Q4 | $62.6B | -1.6% | 28.9% | 0.0% | $18.7B | −$4.1B | $14.7B | 6.4% | — | 11.2% | $172.3B | $1.37 | 8.9 |
| italics below = DCF projection · 10yr Rev CAGR: 0.9% |
| 2026.Q4 | $61.2B | +-2.2% | 29.2% | 2.0% | $17.5B | $0MM | $17.5B | 6.5% | $16.5B | 10.2% | $172.3B | $2.63 | 10.8 |
| 2027.Q4 | $60.3B | +-1.5% | 28.7% | 4.0% | $16.6B | $0MM | $16.6B | 6.7% | $14.6B | 9.6% | $172.3B | $2.49 | 11.4 |
| 2028.Q4 | $59.8B | +-0.8% | 19.5% | 6.0% | $10.9B | $0MM | $10.9B | 6.9% | $9.0B | 6.3% | $172.3B | $1.64 | 17.3 |
| 2029.Q4 | $59.7B | +-0.1% | 25.4% | 8.0% | $14.0B | $0MM | $14.0B | 7.1% | $10.7B | 8.1% | $172.3B | $2.09 | 13.6 |
| 2030.Q4 | $60.0B | +0.6% | 25.4% | 10.0% | $13.7B | −$4.7B | $9.0B | 7.3% | $6.5B | 7.9% | $176.9B | $2.06 | 13.8 |
|
| Term. Yr+ | $71.4B | 4.1% | 31.4% | 20.0% | $17.9B | −$8.6B | $9.4B | 8.6% | $101.9B | 8.6% | — | — | — |
Active scenario IV: $30 (+4.2% vs market)